
Spineology
A St Paul, Minn-based developer of minimally-invasive spinal surgery devices.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor | €0.0 | round |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
investor | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
investor | €0.0 | round | |
N/A | €0.0 | round | |
* | $25.0m | Series A | |
Total Funding | 000k |
Related Content
Spineology Inc. is a medical device company specializing in anatomy-conserving spinal implants and systems. The firm operates in the spinal surgery market, providing tools for surgeons that enable less invasive procedures. The company generates revenue through the sale of its portfolio of spinal products to healthcare institutions.
The company was founded in 1997 by Dr. Stephen Kuslich, a spinal surgeon and serial entrepreneur who had previously co-developed the BAK cage. Dr. Kuslich sought to create a solution for delivering larger spinal implants through smaller incisions, aiming to reduce the invasiveness of spinal fusion surgery. This led to the development of Spineology's core technology. Key milestones include receiving FDA clearance for Stable Vertebral Body Defects in 2003, the first clinical cases using OptiMesh in 2004, and a pivotal De Novo Grant from the FDA for interbody fusion in 2020. In late 2023, longtime CEO John Booth retired, with Brian Snider, a veteran from Alphatec Spine and NuVasive, taking over as the new CEO. In August 2024, the company secured $25 million in a Series AA financing round to accelerate growth.
Spineology's principal product is the OptiMesh® Expandable Interbody Fusion System, based on its proprietary Conform and Expand™ technology. This system is designed for lumbar fusion surgery to treat conditions like degenerative disc disease. The implant is delivered through a small portal, as narrow as one centimeter, and is then filled and expanded within the disc space. This design allows it to dynamically conform to a patient's specific endplate anatomy, creating a large footprint for stability and load-sharing. A significant feature is that the implant is comprised almost entirely of biologics, which promotes a robust environment for bone growth and fusion. Clinical data has shown benefits such as high fusion rates, significant pain relief, shorter hospital stays, and faster recovery for patients.
Keywords: spinal fusion, medical devices, minimally invasive surgery, interbody fusion, expandable implant, OptiMesh, Conform and Expand, spine surgery, degenerative disc disease, De Novo Grant, orthopedic implants, anatomy-conserving, lumbar fusion, medtech, surgical devices, vertebral compression fracture, biologics, spinal reconstruction, clinical trials, patient-specific implant